npj Breast Cancer

Papers
(The TQCC of npj Breast Cancer is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Race-related host and microbe transcriptomic signatures in triple-negative breast cancer694
Biological correlates associated with high-risk breast cancer patients identified using a computational method322
Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancer196
PARG inhibition suppresses breast cancer progression and potentiates immunoresponse through MTDH degradation mediated by E3 ligase ITCH-dependent ubiquitination130
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers129
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab117
Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–2021104
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer99
International survey on invasive lobular breast cancer identifies priority research questions92
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer90
CRISPR screens identify PRMT7 as a therapeutic target to enhance T cell-mediated killing in breast cancer87
A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence77
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors71
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer68
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer68
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice66
Risk factors for second primary cancer in patients who survive breast cancer66
Breastfeeding attributable fraction of triple negative breast cancer in the US64
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial60
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer59
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines57
Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions51
A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study)51
Temporal evolution of breast cancer brain metastases treatments and outcomes50
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer49
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer48
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)47
Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events46
Clinical outcome and proportion of hereditary cancer genes gPV in TNBC: the HEaRTBeat study45
Survival outcomes after omission of surgery for ductal carcinoma in situ43
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer42
Host-derived interleukin-1α drives tumor immunosuppression by reprogramming tumor-associated myeloid cells42
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer41
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays41
Neighborhood deprivation and oncotype DX recurrence scores among Black and White women: the interplay between race, place, and tumor biology39
Circulating tumor DNA validity and potential uses in metastatic breast cancer39
Breast cancer clinical trial participation among diverse patients at a comprehensive cancer center38
Understanding metastasis mixed-treatment responses through genomic analyses37
Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling37
Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature37
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer36
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification36
Kataegis in clinical and molecular subgroups of primary breast cancer34
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer34
Trends in contralateral breast cancer and contralateral prophylactic mastectomy from 2009 to 201633
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment33
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models32
Breast cancers arising in high mammographic density tissue harbor tumor-promoting immune profiles32
Evaluating the clinical utility of ctDNA testing to identify molecular cancer progression – lessons from SERENA-631
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment30
ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin29
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer29
Biomarker, treatment patterns, and survival differences in metastatic triple-negative breast cancer by race in the United States28
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer28
Functional assays for BRCA1 and BRCA2 variant analysis: new tools and their applications28
Prevalence of HER2-low status and outcomes in early-stage HER2-negative breast cancer28
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial27
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program27
Dual ctDNA and CTCs analysis for minimal residual disease detection and relapse monitoring in early-stage breast cancer26
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance26
Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries26
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies26
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer26
Large language model (ChatGPT) as a support tool for breast tumor board25
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer25
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry24
Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study24
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy24
Cook and Move for Your Life, an eHealth intervention for women with breast cancer24
USP7 inhibition perturbs proteostasis and tumorigenesis in triple-negative breast cancer23
Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab23
A systematic review of determinants of breast cancer risk among women with benign breast disease23
Racial disparity in pro-metastatic tumor microenvironment in treatment naïve breast cancer23
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies22
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models22
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers22
SIMD: Synergistic integration mutualistic platform based on single-cell and proteotranscriptomics for drug repositioning22
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer21
Prognostic value of structural variants in early breast cancer patients21
Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor- and stem-like cell expansion in the context of ESR1 mutation21
Predicting short- to long-term breast cancer risk from longitudinal mammographic screening history21
Plasma assay of methylated DNA markers detects recurrent metastatic breast cancer21
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis20
Beyond timing, toward precision: insights from CDK4/6 inhibitor trials in metastatic breast cancer20
Author Correction: Advancing equitable access to innovation in breast cancer20
Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer20
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer20
Phase II trial of anlotinib-chemotherapy combination in pretreated HER2-negative metastatic breast cancer: therapeutic efficacy and proteomic biomarker profiling19
Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2– breast cancer19
Clinical significance of residual microcalcifications after neoadjuvant chemotherapy: MRI response and the subtypes19
MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women19
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy19
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study19
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation19
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer18
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape18
Evaluating mammographic density′s contribution to improve a breast cancer risk model with questionnaire-based and polygenic factors18
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry18
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases18
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence18
Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastases17
The association between local therapies and survival among patients with metastatic inflammatory breast cancer17
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence17
Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer17
Author Correction: Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer17
The different prognostic significance of polysialic acid and CD56 expression in tumor cells and lymphocytes identified in breast cancer17
Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer17
Racial discrimination among women seeking breast cancer care17
Constitutional BRCA1 Methylation is associated with high level of tumoral BRCA1 methylation and homologous recombination deficiency in triple-negative breast cancer17
Proteogenomic characterization of invasive breast tumors in young women17
Plasma C-peptide mammographic features and risk of breast cancer17
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention17
Positron-emission tomography as a predictor of response to first-line cyclin-dependent kinase 4/6 inhibitors in patients with metastatic ER-positive HER2-negative breast cancer16
AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-4116
Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy15
Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer15
Disparities in breast cancer incidence and survival by age, race, and molecular subtype in US women15
Genomic landscape of breast cancer in elderly patients15
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study15
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer15
Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer15
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer15
Agonistic CD40 elicits CD8+ T-cell-dependent primary responses and CD4+ T-cell-dependent long-term immunity in breast cancer15
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer15
Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts15
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib15
Advancing equitable access to innovation in breast cancer14
Artificial intelligence in breast pathology – dawn of a new era14
Artificial intelligence assisted multi-model pathological diagnosis of breast cancer based on multispectral autofluorescence images14
Evaluation of methods to classify ipsilateral breast tumour recurrences as local recurrence or new primary tumour14
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer14
Post-diagnosis weight trajectories and mortality among women with breast cancer14
Identification of racial disparities across MammaPrint and BluePrint subtypes in HR + HER2- breast cancer13
Stromal fibroblastic mutant Trp53 promotes mammary tumor development via enhanced secretion of paracrine factors13
Genomic landscapes of breast cancer in African populations: a systematic review13
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer13
Estrogen receptor β target gene expression reveals novel repressive functions in aggressive breast cancer13
Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study13
Preclinical models of breast cancer metastasis: strengths, limitations, and clinical relevance13
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial13
0.094877004623413